You are here
Phase 2 Study Evaluates Squalamine Lactate in Wet Age-Related Macular Degeneration
"Genaera is pleased to announce the beginning of active enrollment in Study 212," commented Jack Armstrong, President and Chief Executive Officer. "We have assembled an outstanding group of investigators and study sites and are looking forward to obtaining additional information on the most effective dose of EVIZON. This study will provide more detailed information on EVIZON's effects on visual acuity in both affected eyes of patients with exudative AMD. There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections. EVIZON is differentiated from other competitor drugs having demonstrated a positive effect in both study and fellow affected eyes in previous clinical trials. We look forward to confirming that EVIZON is the treatment to meet that medical need."
For information about participation in EVIZON(TM) clinical trials, patients and physicians may call Genaera's Clinical Trial Hotline at (800) 299-9156.
Source: Genaera Corporation